Detalhe da pesquisa
1.
Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials.
Clin Gastroenterol Hepatol
; 22(4): 810-820.e7, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37806372
2.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Lancet
; 399(10342): 2200-2211, 2022 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691323
3.
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Lancet
; 389(10066): 266-275, 2017 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27988142
4.
mTNF reverse signalling induced by TNFα antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease.
Gut
; 62(3): 376-86, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22535372
5.
Safety and tolerability of spesolimab in patients with ulcerative colitis.
Expert Opin Drug Saf
; 22(2): 141-152, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35861588
6.
Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease.
J Med Microbiol
; 57(Pt 12): 1569-1576, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19018031
7.
Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease.
Am J Gastroenterol
; 97(10): 2688-90, 2002 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-12385472